TP53 and prostate cancer: Our present study provides compelling evidence that pharmacological activation of the p53 by blocking the MDM2–p53 interaction is a promising cancer therapeutic strategy and using RITA in combination with Cisplatin not only decrease the toxic effect of Cisplatin by decreasing its dose but also increasing the apoptotic effect, warrants clinical evaluation on both colon and prostate cancer.